Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT02012699
Official study title

Integrated Cancer Repository for Cancer Research

Study summary

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forMesothelioma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 29, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?42 U.S. locations

Locations may change over time.

Who runs it?University of Nebraska

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
University of Nebraska
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Mesothelioma→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Diagnosis/history of cancer
  • Risk for developing cancer or suspicious clinical findings
  • No history of cancer (normal control registry)
  • Able to provide informed consent
  • 19 years of age or older
  • English or Spanish speaking individuals
Reasons someone may not be able to joinExclusion criteria
  • Unable to provide informed consent because of cognitive impairment
  • Non-English or non-Spanish speaking individuals

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Advent HealthGreenwood Village, Colorado
  • Hartford HealthCare Cancer Institute at Manchester Medical HospitalManchester, Connecticut
  • Florida Hospital Memorial Medical CenterDaytona Beach, Florida
  • Florida Hospital DeLandDeLand, Florida
  • Florida Hospital FISHOrange City, Florida
  • Florida Hospital FlaglerPalm Coast, Florida
  • Tallahassee Memorial HospitalTallahassee, Florida
  • Rush-Copley Cancer Care CenterAurora, Illinois
  • Rush-Copley Healthcare CenterYorkville, Illinois
  • Parkview Research CenterFort Wayne, Indiana
  • Methodist Jennie Edmundson HospitalCouncil Bluffs, Iowa
  • Covenant Medical Center, IncWaterloo, Iowa

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 29, 2026. Always confirm current availability with the study team.

View original record ↗